MDST Medicsight

    RNS Number : 6559X
  Medicsight Plc
  27 June 2008
   

 Press Release   27 June 2008

    Medicsight Plc

    ("Medicsight" or "the Company")

    2008 Annual Report and Accounts

    In accordance with Rule 20 of the AIM Rules, Medicsight Plc (AIM: MDST), an industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software, confirms that the Annual Report and Accounts for the year ended 31 January 2008 were posted to
shareholders today and details are available to view on the Company's website at www.medicsight.com.

    - ENDS -

    For further information:
 Medicsight plc
 David Sumner, CEO                    +44 (0)20 7605 7953
                                      www.medicsight.com 
 Nomura Code Securities Limited
 Juliet Thompson, Managing Director   +44 (0)20 777 61200
 Jon Senior                           www.nomuracode.com 

    Media enquiries:
 Abchurch                               Tel: +44 (0) 20 7398 7700
 Heather Salmond                        Tel: +44 (0) 20 7398 7704
 Stephanie Cuthbert / Simone Alves      Tel: +44 (0) 20 7398 7718
 stephanie.cuthbert@abchurch-group.com  www.abchurch-group.com 

    Notes to editors 
    Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software
for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the
colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD
software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD* and LungCAD* software products are seamlessly integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.

    About Computer-Aided Detection
    With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing
challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations
generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due
to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious
regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is
critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful
treatment and a positive therapeutic outcome. 

    About Medicsight's CAD software
    Medicsight's ColonCAD* and LungCAD* software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically
highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such
as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

    Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The
integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of
demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users
to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

    Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product
related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product
development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to
develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
ACSFFMATMMATBJP

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024